ESR1 and breast carcinoma: A 47.1 ORR was further observed in patients with ESR1 mutations [13]—an alteration that is associated with resistance to ER‐targeting therapies, leading to the FDA approval of this PROTAC in 2024 for patients with ER+/HER− advanced breast cancer [20].